

# MAP International

Financial Statements

For The Years Ended September 30, 2024 and 2023



#### REPORT OF INDEPENDENT AUDITOR

The Board of Directors MAP International Brunswick, Georgia

#### **Opinion**

We have audited the accompanying financial statements of MAP International ("the Organization"), which consist of the statements of financial position as of September 30, 2024 and 2023, and the related statements of activities, cash flows, and functional expenses for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of MAP International as of September 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### **Basis for Opinion**

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risk of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

Batts Morrison Wales & Lee, P.A. • Certified Public Accountants

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

BATTS MORRISON WALES & LEE, P.A.

Batta Morrison Woles 4 Lee, P.A.

Orlando, Florida February 12, 2025

# STATEMENTS OF FINANCIAL POSITION

# **ASSETS**

	September 30,			
	2024	2023		
ASSETS				
Cash and cash equivalents	\$ 4,495,408	\$ 2,255,771		
Investments	4,477,762	3,810,307		
Inventory	303,825,016	297,220,961		
Prepaid expenses and other assets	781,641	931,314		
Investments restricted for long-term purposes	3,775,170	3,775,170		
Property and equipment, net	12,229,640	10,489,883		
Total assets	\$ 329,584,637	\$ 318,483,406		
LIABILITIES AND NET ASSETS				
LIABILITIES				
Accounts payable and accrued expenses	\$ 1,191,765	\$ 894,318		
Note payable	4,687,353	3,081,852		
Total liabilities	5,879,118	3,976,170		
NET ASSETS				
Without donor restrictions				
Undesignated	20,609,710	58,554,737		
Designated for minimum state required annuity reserves	29,172	31,269		
Net equity in property and equipment	7,542,287	7,408,031		
Total without donor restrictions	28,181,169	65,994,037		
With donor restrictions	295,524,350	248,513,199		
Total net assets	323,705,519	314,507,236		
Total liabilities and net assets	\$ 329,584,637	\$ 318,483,406		

#### STATEMENTS OF ACTIVITIES

For The Years Ended September 30, 2024 2023 Without Donor With Donor Without Donor With Donor Restrictions Restrictions Total Restrictions Restrictions Total PUBLIC SUPPORT AND REVENUE AND NET ASSETS RELEASED FROM RESTRICTIONS Noncash contributions 35,887,993 \$ 881,518,054 \$ 917,406,047 \$ 389,450,577 \$ 614,399,600 \$1,003,850,177 Cash contributions 9,721,898 4,355,885 14,077,783 8,124,061 4,624,055 12,748,116 Service fees and other revenue, net 3,473,125 491,390 3,964,515 2,663,965 (17,464)2,646,501 Net assets released from time and use restrictions 839,354,178 447,918,448 (447,918,448) (839,354,178) Total public support and revenue and net assets released from restrictions 888,437,194 47,011,151 935,448,345 848,157,051 171,087,743 1,019,244,794 **EXPENSES** Program services Essential medicine distribution 869,709,382 869,709,382 765,351,324 765,351,324 Community health development 26,131,935 26,131,935 31,990,934 31,990,934 Disaster and disease management 22,270,377 22,270,377 35,891,324 35,891,324 Total program services 918,111,694 918,111,694 833,233,582 833,233,582 Supporting activities Fundraising 6,769,807 6,769,807 6,294,421 6,294,421 Management and general 1,368,561 1,368,561 850,458 850,458 Total supporting activities 8,138,368 8,138,368 7,144,879 7,144,879 Total expenses 926,250,062 926,250,062 840,378,461 840,378,461 **CHANGE IN NET ASSETS** (37,812,868) 47,011,151 9,198,283 7,778,590 171,087,743 178,866,333 **NET ASSETS - Beginning of year** 65,994,037 248,513,199 314,507,236 58,215,447 135,640,903 77,425,456 **NET ASSETS - End of year** \$ 28,181,169 \$ 65,994,037 \$ 314,507,236 \$ 295,524,350 \$ 323,705,519 \$ 248,513,199

# STATEMENTS OF CASH FLOWS

	For The Years Ended September 30,		
	2024	2023	
OPERATING CASH FLOWS			
Cash received from contributors	\$ 14,077,783	\$ 12,748,116	
Cash received from service fees and other sources	3,500,724	2,964,370	
Cash paid for operating activities and costs	(14,266,815)	(15,524,864)	
Interest paid	(269,239)	(19,371)	
Net operating cash flows	3,042,453	168,251	
INVESTING CASH FLOWS			
Net purchases of investments	(203,664)	(3,772,809)	
Purchases of and improvements to property and equipment	(2,204,653)	(6,417,197)	
Net investing cash flows	(2,408,317)	(10,190,006)	
FINANCING CASH FLOWS			
Borrowings	1,656,898	3,081,852	
Repayments	(51,397)		
Net financing cash flows	1,605,501	3,081,852	
NET CHANGE IN CASH AND CASH EQUIVALENTS	2,239,637	(6,939,903)	
CASH AND CASH EQUIVALENTS - Beginning of year	2,255,771	9,195,674	
CASH AND CASH EQUIVALENTS - End of year	\$ 4,495,408	\$ 2,255,771	
RECONCILIATION OF CHANGE IN NET ASSETS TO NET OPERATING			
CASH FLOWS			
Change in net assets	\$ 9,198,283	\$ 178,866,333	
Adjustments to reconcile change in net assets to net operating cash flows		, ,	
Depreciation	464,896	344,249	
Net (gain) loss on investments	(463,791)	317,869	
Change in inventory	(6,604,055)	(179,609,156)	
Change in prepaid expenses and other assets	149,673	522,740	
Change in accounts payable and accrued expenses	297,447	(258,150)	
Change in other liabilities	<u></u>	(15,634)	
Net operating cash flows	\$ 3,042,453	\$ 168,251	

# STATEMENT OF FUNCTIONAL EXPENSES For The Year Ended September 30, 2024

		Program	services					
	Essential medicine distribution	Community health development	Disaster and disease management	Total program	Fundraising	Management and general	Total supporting	Total expenses
Salaries and wages	\$ 1,776,575	\$ 327,696	\$ 57,194	\$ 2,161,465	\$ 2,161,022	\$ 472,157	\$ 2,633,179	\$ 4,794,644
Employee benefits	638,262	130,750	22,701	791,713	699,794	151,905	851,699	1,643,412
Total personnel-related expenses	2,414,837	458,446	79,895	2,953,178	2,860,816	624,062	3,484,878	6,438,056
Goods distributed	864,975,606	23,805,773	21,609,624	910,391,003	_	_	_	910,391,003
Outside services	467,524	17,796	10,156	495,476	1,459,880	403,417	1,863,297	2,358,773
Cost of goods distributed	571,608	539,417	405,076	1,516,101	_	_	_	1,516,101
Printing and publications	19,984	780	4,172	24,936	1,070,961	13,475	1,084,436	1,109,372
Grants	_	920,497	80,000	1,000,497	_	_	_	1,000,497
Freight	396,274	334,404	62,418	793,096	14,836	2,050	16,886	809,982
Postage and shipping	2,894	231	61	3,186	762,130	1,954	764,084	767,270
Building and occupancy costs	294,986	10,866	6,209	312,061	153,323	125,938	279,261	591,322
Depreciation	235,410	7,435	5,297	248,142	115,192	101,562	216,754	464,896
Travel	58,362	22,813	1,228	82,403	104,282	24,616	128,898	211,301
Equipment maintenance and rentals	108,001	3,410	2,273	113,684	26,006	22,317	48,323	162,007
Supplies	76,419	2,465	2,127	81,011	64,892	4,523	69,415	150,426
Insurance	69,215	2,186	1,457	72,858	39,485	35,098	74,583	147,441
Other	18,262	5,416	384	24,062	98,004	9,549	107,553	131,615
Total expenses	\$ 869,709,382	\$ 26,131,935	\$ 22,270,377	\$ 918,111,69 <u>4</u>	\$ 6,769,807	<b>\$ 1,368,561</b>	\$ 8,138,368	\$ 926,250,062

# STATEMENT OF FUNCTIONAL EXPENSES For The Year Ended September 30, 2023

		Program	services					
	Essential medicine distribution	Community health development	Disaster and disease management	Total program	Fundraising	Management and general	Total supporting	Total expenses
Salaries and wages	\$ 1,823,829	\$ 308,589	\$ 76,839	\$ 2,209,257	\$ 1,319,041	\$ 297,126	\$ 1,616,167	\$ 3,825,424
Employee benefits	697,822	135,459	29,599	862,880	494,203	93,057	587,260	1,450,140
Total personnel-related expenses	2,521,651	444,048	106,438	3,072,137	1,813,244	390,183	2,203,427	5,275,564
Goods distributed	760,313,046	29,904,111	34,978,916	825,196,073	_	_	_	825,196,073
Outside services	438,910	27,879	18,269	485,058	2,391,662	195,214	2,586,876	3,071,934
Cost of goods distributed	316,884	495,791	680,548	1,493,223	_	_	_	1,493,223
Printing and publications	37,901	3,459	5,365	46,725	1,089,397	10,879	1,100,276	1,147,001
Freight	756,415	199,789	61,372	1,017,576	1,701	581	2,282	1,019,858
Grants	_	852,952	_	852,952	_	_	_	852,952
Postage and shipping	16,518	531	709	17,758	630,128	5,094	635,222	652,980
Building and occupancy costs	243,061	9,367	10,336	262,764	37,050	46,512	83,562	346,326
Depreciation	220,734	7,121	10,003	237,858	43,362	63,029	106,391	344,249
Other	67,712	6,837	2,859	77,408	123,919	54,802	178,721	256,129
Travel	102,440	28,173	2,979	133,592	70,663	19,649	90,312	223,904
Insurance	111,224	3,553	4,748	119,525	27,563	40,693	68,256	187,781
Supplies	107,622	3,723	4,601	115,946	52,154	6,601	58,755	174,701
Equipment maintenance and rentals	97,206	3,600	4,181	104,987	13,578	17,221	30,799	135,786
Total expenses	\$ 765,351,32 <u>4</u>	<b>\$ 31,990,934</b>	<b>\$</b> 35,891,324	\$ 833,233,582	<b>\$</b> 6,294,421	\$ 850,458	\$ 7,144,879	<u>\$ 840,378,461</u>

#### NOTES TO FINANCIAL STATEMENTS

#### **NOTE A - NATURE OF ACTIVITIES**

MAP International ("the Organization") was established in 1965 as an Illinois not-for-profit corporation. The Organization's purpose is to promote the total health of people living in the world's impoverished communities. The Organization provided access to health services and essential medicines in 92 and 96 countries worldwide during the years ended September 30, 2024 and 2023, respectively. In fulfilling its purpose, the Organization distributes gifts in-kind, including donated medicines, equipment, and supplies which are primarily donated by pharmaceutical companies. The Organization also receives cash contributions from individuals, churches, and other organizations.

The Organization works with its partners to accomplish the following primary program activities:

Essential medicine distribution – The Organization provides critical life-saving medications that are always in short supply in impoverished countries with limited health care. Medicines and medical supplies are provided to hospitals, clinics, refugee centers, and physicians in other countries as they are needed. In addition, the Organization's specially designed travel packs are used by Christian health personnel and mission groups on short-term missions and include an assortment of some of the most critically needed medicines and supplies. The Organization also provides medicines and supplies for rapid response to humanitarian emergencies around the world including, at times, in the United States.

Community health development – Total health training workshops teach medical, cultural, and biblical principles of health in remote, rural areas from the Amazon to Kenya. The MAP International Fellowship provides opportunities for medical students to serve short-term missions in Christian hospitals around the world.

*Disaster and disease management* – The Organization's programs provide vital medicines, educational materials, and training to aid in the treatment and prevention of diseases. The Organization provides a variety of disease prevention and eradication programs, including education and prevention programs that benefit communities in Latin America and Africa.

#### **NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

### Revenue recognition

The Organization recognizes cash contributions as revenue when the contributions are received by the Organization. Contributions received are recorded as without or with donor restrictions depending on the existence and/or nature of any donor restrictions. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the accompanying statements of activities as "net assets released from time and use restrictions." Contributions of noncash assets are recorded at estimated fair value on the date of the gift.

### Cash and cash equivalents

The Organization considers investment instruments purchased or donated with original maturities of three months or less to be cash and cash equivalents.

#### <u>Inventory</u>

Inventory consists of humanitarian relief goods which were not yet distributed to beneficiaries as of year-end. Inventory is recorded at estimated fair value on the date of the gift. Purchased inventory is stated at the lower of cost or net realizable value.

#### <u>Investments restricted for long-term purposes</u>

Investments restricted for long-term purposes consist of mutual funds, government money market funds, and stocks which are restricted pursuant to endowment agreements.

NOTES TO FINANCIAL STATEMENTS

# NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

#### **Property and equipment**

Property and equipment are stated at cost, if purchased, or estimated fair value on the date of donation, if donated. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets.

#### **Net assets**

Net assets without donor restrictions are available for use at the discretion of the Board of Directors and/or management for general operating purposes. From time to time, the Board may designate a portion of these net assets for specific purposes which makes them unavailable for use at management's discretion. The Board has designated a portion of net assets without donor restrictions for minimum state required annuity reserves. Net assets with donor restrictions consist primarily of amounts held by the Organization for use toward specific projects or for distribution in specific geographic areas.

#### **Noncash contributions**

The Organization receives donations of pharmaceuticals and medical supplies for use in relieving suffering for those in need throughout the world through its various program activities. Certain noncash contributions are donor-restricted for specific geographic regions. Noncash contributions are recognized as revenue at estimated fair value on the date the gifts are received and are recognized as expenses when they are shipped from the Organization's warehouse or the date upon which the Organization no longer exercises practical control over those items. The Organization's policy is to distribute donated pharmaceuticals and medical supplies and not to monetize noncash contributions of pharmaceuticals and medical supplies.

The Organization only records the value of noncash contributions over which it exercises variance power. In general, management estimates the fair value of donated pharmaceuticals using "wholesale acquisition cost," listed in reference materials including First Databank and IBM Micromedex RED BOOK ("RED BOOK"), which are widely-used drug and pricing reference guides for the pharmaceutical industry in the United States. Management may apply discounts to the prices in First Databank and RED BOOK depending on the gift's condition or other factors. For gifts in-kind of pharmaceuticals and medical supplies that are sold in the United States market, the Organization has determined that the U.S. is the principal or most advantageous market for purposes of estimating fair value. If prices for a particular item are not available in First Databank or RED BOOK, MAP estimates fair value using other online pricing sources. The Organization considers the valuation practices used for noncash contributions to be consistent with industry standards.

## **Functional allocation of expenses**

The statements of functional expenses present expenses by function and natural classification. Expenses directly attributable to a specific functional area are reported as expenses of those functional areas. Indirect costs that benefit multiple functional areas are allocated among the various functional areas based primarily on employee time and space utilization.

#### **Income taxes**

The Organization is exempt from federal income tax as an organization described in Section 501(c)(3) of the Internal Revenue Code and is generally exempt from applicable state income taxes. The Organization is further classified as a public charity and not a private foundation for federal tax purposes. The Organization has not incurred unrelated business income taxes. As a result, no income tax provision or liability has been provided for in the accompanying financial statements.

NOTES TO FINANCIAL STATEMENTS

# NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

#### **Use of estimates**

Management uses estimates and assumptions in preparing the accompanying financial statements. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and reported revenues and expenses. Significant estimates used in preparing these financial statements include those related to the estimated fair value of investments, the useful lives of property and equipment, and the estimated fair value of noncash contributions. Actual results could differ from the estimates.

#### Reclassifications

Certain amounts included in the September 30, 2023 financial statements have been reclassified to conform to classifications adopted during the year ended September 30, 2024. The reclassifications had no material effect on the accompanying financial statements.

#### **Subsequent events**

The Organization has evaluated for possible financial reporting and disclosure subsequent events through the date of the report of independent auditor, the date as of which the accompanying financial statements were available to be issued.

#### **NOTE C - LIQUIDITY AND AVAILABILITY OF RESOURCES**

Financial assets available for general expenditure within one year of the date of the statements of financial position are as follows:

	Septem	iber 30,
	2024	2023
Financial assets available: Cash and cash equivalents Investments (including "investments restricted for long-term	\$ 4,495,408	\$ 2,255,771
purposes") Accounts receivable, net (included in "prepaid expenses and other	8,252,932	7,585,477
assets")	353,362	349,798
Total financial assets available within one year	13,101,702	10,191,046
Less amounts unavailable for general expenditure within one year due to:	(2.555.450)	(2.555.450)
Endowments Designated for minimum state required annuity reserves	(3,775,170) (29,172)	(3,775,170) (31,269)
Net financial assets available within one year	<u>\$ 9,297,360</u>	\$ 6,384,607

The Organization is primarily supported by contributions. As part of the Organization's liquidity management, it structures its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Certain net assets with donor restrictions are available for general expenditure within one year of September 30, 2024 and 2023, because the restrictions on net assets are expected to be met by conducting the normal activities of the Organization in the coming year. The state of Georgia requires issuers of annuities to maintain \$300,000 in available liquid assets. Management believes the Organization has sufficient financial assets available for general operations that may be drawn upon in the event of unanticipated financial distress or immediate liquidity need. As of September 30, 2024, the Organization also had a revolving line of credit in an amount up to \$3,000,000 as an additional source of liquidity (further described in Note G).

#### NOTES TO FINANCIAL STATEMENTS

#### **NOTE D - CONCENTRATIONS**

The Organization maintains its cash and cash equivalents in deposit accounts which may not be federally insured, may exceed federally insured limits, or may be insured by an entity other than an agency of the federal government. The Organization has not experienced any losses in such accounts, and believes it is not exposed to any significant credit risk related to cash and cash equivalents.

During the years ended September 30, 2024 and 2023, approximately 44% and 61%, respectively, of total noncash contribution revenue was sourced from the Organization's three largest donors. The three largest donors in any given year generally varies among a group of approximately 20 donors.

#### **NOTE E - FAIR VALUE MEASUREMENTS**

Accounting principles generally accepted in the United States ("GAAP") define fair value for an investment generally as the price an organization would receive upon selling the investment in an orderly transaction to an independent buyer in the principal or most advantageous market for the investment. The information available to measure fair value varies depending on the nature of each investment and its market or markets. Accordingly, GAAP recognizes a hierarchy of "inputs" an organization may use in determining or estimating fair value. The inputs are categorized into "levels" that relate to the extent to which an input is objectively observable and the extent to which markets exist for identical or comparable investments. In determining or estimating fair value, an organization is required to maximize the use of observable market data (to the extent available) and minimize the use of unobservable inputs. The hierarchy assigns the highest priority to unadjusted quoted prices in active markets for identical items (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Following is a description of each of the three levels of input within the fair value hierarchy:

Level 1 – unadjusted quoted market prices in active markets for identical items

Level 2 – other significant observable inputs (such as quoted prices for similar items)

Level 3 – significant unobservable inputs

The estimated fair value of certain assets measured on a recurring basis at September 30, 2024, are as follows:

	_	<u>Total</u>		Level 1		Level 2		Level 3	
Mutual funds	\$	5,065,511	\$	5,065,511	\$	_	\$	_	
Government money market funds		1,563,263		1,563,263		_		_	
Stocks		1,149,956		1,149,956		_		_	
Alternative investments		453,804		_		_		453,804	
U.S. Treasury notes		20,398		20,398	_				
Total	\$	8,252,932	\$	7,799,128	\$		\$	453,804	

The activity for Level 3 assets during the year ended September 30, 2024 was immaterial.

NOTES TO FINANCIAL STATEMENTS

# **NOTE E - FAIR VALUE MEASUREMENTS (Continued)**

The estimated fair value of certain assets measured on a recurring basis at September 30, 2023, are as follows:

	<u> </u>		Level 1		Level 2		Level 3	
Mutual funds Government money market	\$	4,160,340	\$	4,160,340	\$	_	\$	_
funds		3,400,507		3,400,507		_		_
U.S. Treasury notes		24,630		24,630			_	
Total	\$	7,585,477	\$	7,585,477	\$		\$	

#### **NOTE F - PROPERTY AND EQUIPMENT**

Property and equipment consisted of the following:

	<u>September 30,</u>
Category	2024 2023
Land and land improvements Buildings and improvements Furniture and equipment Construction in process	\$ 702,036 \$ 702,036 13,721,556 5,650,098 3,518,402 3,446,571 
Total property and equipment	18,001,676 15,865,585
Less: Accumulated depreciation	<u>(5,772,036)</u> <u>(5,375,702</u> )
Net property and equipment	<u>\$ 12,229,640</u> <u>\$ 10,489,883</u>

Depreciation expense amounted to \$464,896 and \$344,249 during the years ended September 30, 2024 and 2023, respectively.

## NOTE G - NOTE PAYABLE AND REVOLVING LINE OF CREDIT

### Construction loan

During the year ended September 30, 2023, the Organization entered into a promissory note with a bank with an available amount up to approximately \$4,739,000 for the construction of a warehouse. As of September 30, 2024 and 2023, the outstanding balance of the promissory note was \$4,687,353 and \$3,081,852, respectively. The promissory note required monthly interest-only payments through May 2024 at a fixed rate of 6.15% per annum. Commencing in June 2024, the promissory note requires 59 consecutive monthly payments of \$34,615 (including principal and interest at a fixed rate of 6.15% per annum). A balloon payment is due at maturity in May 2029. The promissory note is secured by certain property and other assets as detailed in the security agreement.

NOTES TO FINANCIAL STATEMENTS

# NOTE G - NOTE PAYABLE AND REVOLVING LINE OF CREDIT (Continued)

Approximate future maturities of the note payable is as follows:

Year Ending	
September 30,	
2025	¢ 120,000
2025	\$ 130,000
2026	138,000
2027	146,000
2028	156,000
2029	4,117,000
	h
Total	<u>\$ 4,687,000</u>

During the years ended September 30, 2024 and 2023, the Organization incurred interest expense of approximately \$283,000 and \$33,000, respectively.

## Revolving line of credit

The Organization has a revolving line of credit with a bank with an available balance of up to \$3,000,000. Interest on any outstanding balance is payable monthly at the prime rate less 0.25% per annum (7.75% and 8.25% as of September 30, 2024 and 2023, respectively). The revolving line of credit is secured by a negative pledge agreement regarding certain property and matures in December 2025. No draws were made on the line of credit during the years ended September 30, 2024 and 2023, and no balance was outstanding on the line of credit as of September 30, 2024 and 2023.

## **NOTE H - RESTRICTIONS ON NET ASSETS**

Net assets were restricted by donors for the following purposes during the year ended September 30, 2024:

	Balance October 1	Contributions and investment income	Releases	Balance September 30
Pharmaceuticals and other gifts in-kind restricted for certain geographic regions	\$ 242,016,541	\$ 881,518,053	\$ (835,976,437)	
Special projects	1,767,497	3,926,212	(2,680,981)	3,012,728
Endowment appreciation	557,168	491,390	_	1,048,558
Disaster relief	<u>396,823</u>	429,674	<u>(696,760</u> )	129,737
Subtotal	244,738,029	886,365,329	(839,354,178)	291,749,180
Endowments:				
Program activities endowment	t 2,561,443	_	_	2,561,443
International fellowship endowment	1,213,727			1,213,727
Subtotal	3,775,170			3,775,170
Total	\$ 248,513,199	<u>\$ 886,365,329</u>	<u>\$ (839,354,178</u> )	<u>\$ 295,524,350</u>

NOTES TO FINANCIAL STATEMENTS

## **NOTE H - RESTRICTIONS ON NET ASSETS (Continued)**

Net assets were restricted by donors for the following purposes during the year ended September 30, 2023:

		Balance October 1	Contributions and investment income (loss)	Releases	Balance September 30
Pharmaceuticals and other gifts in-kind restricted for certain geographic regions	\$	72,014,736	\$ 614,399,600	\$ (444,397,795)	\$ 242,016,541
Special projects		564,617	3,709,076	(2,506,196)	1,767,497
Endowment appreciation		574,632	(17,464)		557,168
Disaster relief		496,301	914,979	(1,014,457)	396,823
Subtotal		73,650,286	619,006,191	_(447,918,448)	244,738,029
Endowments:					
Program activities endowment	t	2,561,443	_	_	2,561,443
International fellowship endowment		1,213,727			1,213,727
Subtotal		3,775,170			3,775,170
Total	\$	77,425,456	<u>\$ 619,006,191</u>	<u>\$ (447,918,448</u> )	<u>\$ 248,513,199</u>

Distributions from the program activities endowment are available to support the general operations of the Organization. Distributions from the international fellowship endowment are available for medical scholarships. The Organization preserves the estimated fair value of all original endowment gifts as of the gift date, which management deems is in compliance with state law. Accordingly, the Organization classifies as "endowment corpus" (a) the original value of gifts donated to the permanent endowment and (b) the original value of subsequent gifts to the permanent endowments.

The Organization has adopted investment policies for endowment assets that attempt to provide a predictable stream of funding to supported programs while seeking to maintain the purchasing power of the endowment assets and to preserve the invested capital. The stated investment goal is an absolute rate of return of four percent per annum over a five to ten year period. The Organization emphasizes spending on current or near-term programs.

The spending policy provides flexibility, and the Organization seeks the advice of investment counsel, as well as management and certain committees of the Board, when determining amounts to be spent on supported programs. The Organization considers all endowment earnings to be restricted until such time that the earnings are appropriated for expenditure.

NOTES TO FINANCIAL STATEMENTS

## **NOTE H - RESTRICTIONS ON NET ASSETS (Continued)**

The Organization's endowment activity for the years ended September 30, 2024 and 2023, is as follows:

	Wit				
	<u>Time/P</u>	<u>Time/Purpose</u>		ual	 Total
Endowment net assets, October 1, 2022 Investment loss, net Appropriated for expenditure	-	574,632 (17,464) ——	\$ 3,77	5,170 — —	\$ 4,349,802 (17,464) —
Endowment net assets, September 30, 2023 Investment gain, net Appropriated for expenditure		557,168 491,390 —	3,77	5,170 — —	 4,332,338 491,390 —
Endowment net assets, September 30, 2024	<u>\$ 1,0</u>	)48 <u>,558</u>	\$ 3,77	<u>5,170</u>	\$ 4,823,728

## **NOTE I - NONCASH CONTRIBUTIONS**

Noncash contributions recognized in the statements of activities included:

	September 30,	
<u>Category</u>	2024 2023	-
Prescription drugs	\$ 823,174,507 \$ 915,745,108	
Over-the-counter medicines	61,357,992 49,292,383	L
Medical supplies and equipment	<u>32,873,548</u> <u>38,812,688</u>	<u>}</u>
Total noncash contributions	<u>\$ 917,406,047</u> <u>\$1,003,850,17</u>	<u>7</u>

The Organization distributed gifts in-kind to its partners totaling \$910,391,003 and \$825,196,073 during the years ended September 30, 2024 and 2023, respectively. Of these amounts, approximately \$3,083,000 and \$11,306,000, respectively, was shipped directly from the donor to the Organization's partners.

## NOTE J - RETIREMENT PLAN

The Organization offers a defined contribution retirement plan which covers substantially all employees. The Organization contributed approximately \$290,000 and \$246,000 to the defined contribution retirement plan during the years ended September 30, 2024 and 2023, respectively.